Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

D2G Oncology Inc
Profile last edited on: 9/21/22      CAGE: 87FM3      UEI: CV5BLXMMLFJ3

Business Identifier: Relating drugs to genotypes to transform precision cancer therapeutics.
Year Founded
2018
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

353 Lowell Avenue
Palo Alto, CA 94301
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Spun out of Stanford, D2G Oncology is focused on leveraging quantitative and multiplexed functional cancer genomics to relate drugs to genotypes thereby to transform precision cancer therapeutics.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$1,134,487
Phase II Dollars
$865,070
Total Awarded
$1,999,557

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $1,999,557
Project Title: Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-Seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform

Key People / Management

  Jonathan MacQuitty -- CEO

  Sheri Haynes

  Joseph Juan -- Head of Cancer Biology | Director of Business Development

  Dmitr Petrov -- Cofounder

  Monte Winslow -- Co-Founder

  Ian Paul Winters -- Co-Founder & Director of Research

Company News

There are no news available.